Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4521 [18F]FDG (FDG) PET/CT metrics as prognostic biomarkers in the AGITG NABNEC trial

Introduction: NABNEC was a prospective phase II trial investigating carboplatin/nab-paclitaxel in patients with advanced Grade 3 NENs (NCT02215447).

Conference:

Presenting Author: Kong G

Authors: Kong G, Ayati N, Brown C, Siu D, Mak W,

Keywords: Prognostic marker, prospective trial, chemotherapy, PET imaging, FDG, metabolic tumour volume, suv,

#4475 Retreatment with [177Lu]Lu-DOTATATE in neuroendocrine tumours: Outcomes in progression-free survival and toxicity – Our experience

Introduction: Multiple systemic treatments exist for advanced or metastatic NETs, including somatostatin analogues, targeted agents, chemotherapy, and peptide receptor radionuclide therapy (PRRT). PRRT has shown maximum benefit for response rate, progression-free survival (PFS), and overall survival (OS) with favourable toxicity.

Conference:

Presenting Author: Salcedo Cortes S

Authors: Salcedo Cortes S, Mari Hualde A, Ardila Manjarés E, Guzman Cruz A, Orcajo Rincón J,

Keywords: Neuroendocrine tumour (NET), Peptide receptor radionuclide therapy (PRRT), [177Lu]Lu-DOTATATE, Retreatment (R-PRRT), Toxicity, Progression-free survival (PFS), Overall survival (OS),

#4474 Follow-up 68Ga-DOTATATE PET/CT post resection of small bowel neuroendocrine neoplasia

Introduction: Surgery remains the mainstay of treatment for resectable neuroendocrine neoplasms (NENs). Post resection, guidelines suggest a risk-based approach to surveillance, with 3-6 monthly imaging based on tumour biology. However, there is a paucity of data regarding the timing of surveillance imaging for resected well-differentiated NEN.

Conference:

Presenting Author:

Authors: Sabahi Z, Chan D, Darbhamulla S, Mok C, Samra J,

Keywords: Neuroendocrine, 68Ga-DOTATATE PET/CT, Small bowel,

#4449 Treatment of MiNEN with peptide receptor radionuclide therapy

Introduction: Mixed non-neuroendocrine and neuroendocrine neoplasms (MiNENs) of gastrointestinal tract are rare tumours with characteristic histological features include at least 30% of both neuroendocrine and non-neuroendocrine components of the whole neoplasm. They are usually treated with surgical resection and chemotherapy in advanced disease. However, there is scarcity of data for the use of peptide receptor radionuclide therapy (PRRT) in these tumours.

Conference:

Presenting Author: Shekhda K

Authors: Shekhda K, Luong T, Paterson A, Navalkissoor S, Krell D,

Keywords: MiNEN, PRRT, DOTATATE,

#4421 Head-to-head comparison of 18F-AlF-NOTA-JR11 PET/MR and 68Ga-DOTATATE PET/CT in patients with neuroendocrine tumours: A prospective study

Introduction: PET/MR combines the molecular advantages of PET with excellent morphologic and anatomic delineation of MRI.18F-AlF-NOTA-JR11, a novel SSTR antagonist with a high affinity for SSTR2, has the potential to perform better than SSTR agonists in neuroendocrine tumour imaging.

Conference:

Presenting Author: Yu J

Authors: Jin X, Xie Q, Lu M, Li J, Yang Z,

Keywords: neuroendocrine tumour, PET/MR, SSTR antagonist, 18F-AlF-NOTA-JR11,